{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:43Z","timestamp":1792831063006,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40265-026-02384-0","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:28:15Z","timestamp":1788928095000},"page":"1935-1940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Atacicept: First Approval"],"prefix":"10.1007","volume":"86","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"1","key":"2384_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/23995270.2026.2664411","volume":"6","author":"J Barratt","year":"2026","unstructured":"Barratt J, Lafayette R. Atacicept: dual BAFF\/APRIL inhibition and clinical evidence in IgA nephropathy. Future Rare Dis. 2026;6(1):1\u201312.","journal-title":"Future Rare Dis"},{"key":"2384_CR2","unstructured":"Vera Therapeutics Inc. Form 10-K. 2026. https:\/\/ir.veratx.com\/static-files\/2d388637-5e4c-4090-ad47-1314b8afcf71. Accessed 26 Aug 2026."},{"key":"2384_CR3","unstructured":"Vera Therapeutics. Vera Therapeutics announces U.S. FDA granted Priority Review to Biologics License Application for atacicept for treatment of adults with IgA nephropathy [media release]. 7 Jan 2026. http:\/\/www.veratx.com."},{"key":"2384_CR4","unstructured":"Vera Therapeutics. Vera Therapeutics receives U.S. FDA Breakthrough Therapy Designation for atacicept in immunoglobulin A nephropathy (IgAN) [media release]. 28 May 2024. http:\/\/www.veratx.com."},{"key":"2384_CR5","unstructured":"U.S. Food & Drug Administration. FDA Approves new treatment to reduce proteinuria in adults with primary immunoglobulin A nephropathy [media release]. 7 Jul 2026. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-new-treatment-reduce-proteinuria-adults-primary-immunoglobulin-nephropathy."},{"key":"2384_CR6","unstructured":"Vera Therapeutics. Vera Therapeutics receives FDA accelerated approval for TRUTAKNA(Tm) for adult patients with primary IgA nephropathy [media release]. 7 Jul 2026. http:\/\/www.veratx.com."},{"key":"2384_CR7","unstructured":"Vera Therapeutics Inc. TRUTAKNA\u2122 (atacicept-vymj) injection, for subcutaneous use: US prescribing information. 2026. https:\/\/webfiles.veratx.com\/docs\/TRUTAKNA_Prescribing_Information.pdf. Accessed 26 Aug 2026."},{"key":"2384_CR8","unstructured":"ZymoGenetics, Serono S. A. ZymoGenetics and Serono to collaborate on a novel therapeutic approach for autoimmune disease [media release]. 4 Sep 2001. http:\/\/www.zymogenetics.com."},{"key":"2384_CR9","unstructured":"Merck KGaA. Merck Serono is launched [media release]. 8 Jan 2007. http:\/\/www.merckserono.ch."},{"key":"2384_CR10","unstructured":"Merck KGaA. Merck KGaA acquires majority shareholding in Serono S.A [media release]. 5 Jan 2007. http:\/\/www.merck.de."},{"key":"2384_CR11","unstructured":"ZymoGenetics Inc. ZymoGenetics and Merck Serono restructure partnership [media release]. 3 Sep 2008. http:\/\/www.zymogenetics.com."},{"key":"2384_CR12","unstructured":"Merck A. G. Merck announces out-licensing agreement for investigational atacicept with Vera Therapeutics [media release]. 9 Nov 2020. http:\/\/www.merckgroup.com."},{"issue":"7","key":"2384_CR13","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00228-007-0311-7","volume":"63","author":"A Munafo","year":"2007","unstructured":"Munafo A, Priestley A, Nestorov I, et al. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol. 2007;63(7):647\u201356.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2384_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s13318-019-00575-7","volume":"45","author":"D Willen","year":"2020","unstructured":"Willen D, Uhl W, Wolna P, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of atacicept in a randomized trial in healthy Caucasian and Japanese subjects. Eur J Drug Metab Pharmacokinet. 2020;45(1):27\u201340.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"7","key":"2384_CR15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1056\/NEJMoa2510198","volume":"394","author":"R Lafayette","year":"2026","unstructured":"Lafayette R, Barbour SJ, Brenner RM, et al. A phase 3 trial of atacicept in patients with IgA nephropathy. N Engl J Med. 2026;394(7):647\u201357.","journal-title":"N Engl J Med"},{"issue":"6","key":"2384_CR16","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","volume":"105","author":"R Lafayette","year":"2024","unstructured":"Lafayette R, Barbour S, Israni R, et al. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 2024;105(6):1306\u201315.","journal-title":"Kidney Int"},{"issue":"4","key":"2384_CR17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1681\/ASN.0000000541","volume":"36","author":"J Barratt","year":"2025","unstructured":"Barratt J, Barbour SJ, Brenner RM, et al. Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy. J Am Soc Nephrol. 2025;36(4):679\u201387.","journal-title":"J Am Soc Nephrol"},{"key":"2384_CR18","unstructured":"Barratt J, Lafayette R, Brenner R, et al. PIONEER: a basket trial of atacicept in autoimmune-mediated glomerular diseases: preliminary findings from the IgA nephropathy cohort [poster]. In: 63rd European Renal Association (ERA) Congress. 2026."},{"issue":"8","key":"2384_CR19","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.ekir.2022.05.017","volume":"7","author":"J Barratt","year":"2022","unstructured":"Barratt J, Tumlin J, Suzuki Y, et al. Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria. Kidney Int Rep. 2022;7(8):1831\u201341.","journal-title":"Kidney Int Rep"},{"issue":"2 Suppl","key":"2384_CR20","doi-asserted-by":"publisher","first-page":"S211","DOI":"10.1016\/j.ekir.2024.11.405","volume":"10","author":"J Barratt","year":"2025","unstructured":"Barratt J, Brenner R, Cooper K, et al. ORIGIN Extend: a long-term extension study of atacicept in IgAN [abstract no. WCN25-2522 plus poster WCN24-AB-2522]. Kidney Int Rep. 2025;10(2 Suppl):S211.","journal-title":"Kidney Int Rep."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02384-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02384-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02384-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:11:56Z","timestamp":1792829516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02384-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2384"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02384-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"16 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah A. Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}